好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

InSPECT: An Investigation of the Effects of Short-Term Treatment with Pramipexole or Levodopa on [123I] B-CIT and SPECT Imaging in Early Parkinson Disease
Movement Disorders
(-)
159
Authors/Disclosures
Kenneth L. Marek, MD (IND) Dr. Marek has received personal compensation for serving as an employee of IND. Dr. Marek has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for invicro. Dr. Marek has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche. Dr. Marek has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi. Dr. Marek has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biohaven. Dr. Marek has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for takeda. Dr. Marek has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Denali. Dr. Marek has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Koneksa. Dr. Marek has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Xingimaging. Dr. Marek has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neuron23. Dr. Marek has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lilly. Dr. Marek has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biohaven. Dr. Marek has received research support from Michael J Fox Foundation.
Maria C. Zurru, MD No disclosure on file
Duarte G. Machado, MD, FAAN (Hartford Healthcare Neurology) Dr. Machado has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Supernus. Dr. Machado has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurocrine. Dr. Machado has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Abbvie. Dr. Machado has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Adamas. Dr. Machado has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Ipsen. Dr. Machado has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Kyowa Kirin. Dr. Machado has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merz. Dr. Machado has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Neurocrine. Dr. Machado has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sunovion. Dr. Machado has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Teva.
No disclosure on file
Danna L. Jennings, MD (Denali Therapeutics) Dr. Jennings has received personal compensation for serving as an employee of Denali Therapeutics . Dr. Jennings has received stock or an ownership interest from Denali Therapeutics.
No disclosure on file
Rowena Desailly-Chanson, MD (Medical Group of the Carolinas) No disclosure on file
Alexander Kalin Alexander Kalin has received personal compensation for serving as an employee of Mitsubishi Tanabe Pharma America, Inc..
John P. Seibyl, MD Dr. Seibyl has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Invicro. Dr. Seibyl has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biogen. Dr. Seibyl has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Life Molecular Imaging. Dr. Seibyl has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche. Dr. Seibyl has received stock or an ownership interest from Invicro.
No disclosure on file
No disclosure on file